The FDA approved Awiqli (insulin icodec-abae) injection 700 units/mL on March 26, 2026, as the first and only once-weekly basal insulin for adults with type 2 diabetes to improve glycemic control alongside diet and exercise.
Awiqli reduces basal insulin injections from seven daily to one weekly, administered via Awiqli FlexTouch on the same day each week.
Approval based on ONWARDS phase 3a program:
four trials with ~2,680 adults showing A1C reductions comparable to daily basal insulins and a consistent safety profile.
Awiqli addresses challenges of daily injections, offering personalized care for type 2 diabetes patients.
Not approved for children or adolescents; common side effects include hypoglycemia, injection site reactions, and weight gain.